GH/IGF-1轴在代谢相关性脂肪肝病中的研究进展  

Research progress of GH/IGF-1 axis in metabolic-associated fatty liver disease

作　　者：鲁佳慧 冯荣 吴梦 刘洁[1] LU Jiahui;FENG Rong;WU Meng;LIU Jie(Department of Endocrinology,Affiliated Hospital of Hebei University,Hebei Province,Baoding071000,China;Department of Cardiology,Affiliated Hospital of Hebei University,Hebei Province,Baoding071000,China;Department of Pulmonary and Critical Care Medicine,Affiliated Hospital of Hebei University,Hebei Province,Baoding071000,China)

机构地区：[1]河北大学附属医院内分泌科,河北保定071000 [2]河北大学附属医院心血管内科,河北保定071000 [3]河北大学附属医院呼吸与危重症学科,河北保定071000

出　　处：《中国医药导报》2024年第25期71-75,共5页China Medical Herald

摘　　要：代谢相关性脂肪肝病(MAFLD)影响约1/4的成年人,是肝硬化和肝癌发展的主要风险之一,目前并无特定药物治疗。生长激素(GH)抑制肝脏脂肪生成,胰岛素样生长因子1(IGF-1)抑制肝脏炎症和纤维化;肠-肝轴破坏是MAFLD进展的重要因素,GH/IGF-1轴可调节肠-肝轴延缓MAFLD进展,展现治疗MAFLD的巨大潜力;胰岛素样生长因子结合蛋白(IGFBP)作为分泌蛋白,在MAFLD发展中逐渐被揭示。本文综述GH/IGF-1轴及IGFBP1~3与MAFLD的作用机制,并从补充GH/IGF-1的角度探讨治疗MAFLD的可行性。Metabolic-associated fatty liver disease(MAFLD)affects about 1/4 of adults and is one of the main risks for the development of cirrhosis and liver cancer.Currently,there is no specific drug treatment available.Growth hormone(GH)inhibits liver fat production,while insulin-like growth factor 1(IGF-1)inhibits liver inflammation and fibrosis;disruption of gut-liver axis is an important factor in the progression of MAFLD,and GH/IGF-1 axis can regulate gut-liver axis to delay the progression of MAFLD,demonstrating great potential for treating MAFLD;insulin-like growth factor binding protein(IGFBP),as a secreted protein,is gradually being revealed in the development of MAFLD.This article reviews the mechanism of action of GH/IGF-1 axis and IGFBP1-3 on MAFLD,and explores the feasibility of treating MAFLD from the perspective of supplementing GH/IGF-1.

关 键 词：生长激素/胰岛素样生长因子1轴 代谢相关性脂肪肝病 胰岛素样生长因子结合蛋白家族 肠-肝轴 

分 类 号：R589[医药卫生—内分泌]